Valeant Overview

FULL DESCRIPTION

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company focuses on eye health, dermatology and neurology therapeutic classes, primarily on branded generics, OTC products and medical devices. The Company operates through two segments: developed markets and emerging markets.

Developed Markets

The Company’s developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products, as well as alliance and contract service revenues, in the areas of eye health, dermatology and podiatry, aesthetics, and dentistry; sales in the United States of pharmaceutical products indicated for the treatment of neurological and other diseases, as well as alliance revenue from the licensing of various products it developed or acquired, and pharmaceutical products, OTC products, and medical device products sold in Canada, Australia, New Zealand, Western Europe and Japan.

The Company’s pharmaceutical products are Solodyn, a prescription oral antibiotic; Wellbutrin XL is an extended-release formulation of bupropion indicated for the treatment of depressive disorder in adults; Jublia (efinaconazole 10% topical solution), is a topical azole indicated for the treatment of onychomycosis of the toenails (toenail fungus); Xenazine is indicated for the treatment of chorea associated with Huntington’s disease; Targretin Capsules is a retinoid indicated for treatment of Cutaneous T-Cell Lymphoma; Arestin (minocycline hydrochloride) is a subgingival sustained-release antibiotic; Zovirax is a...